What question did this study set out to answer?

To evaluate the efficacy and safety of weekly adalimumab compared with placebo for the treatment of hidradenitis suppurativa.

August 3, 2016New England Journal of Medicine

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

View Full Paper

Ask AI

Bookmark

Authors

AKAlexa B. KimballBeth Israel Deaconess Medical Center MOMartin M. OkunAtkins (United States)DWDavid WilliamsUniversity of North Carolina Health Care

Discussion

Member takes

Implication

Randomized trials demonstrate higher 12-week response rates with adalimumab in hidradenitis suppurativa, indicating therapeutic efficacy without added serious adverse events.

Key Points

To evaluate the efficacy and safety of weekly adalimumab compared with placebo for the treatment of hidradenitis suppurativa.
Conducted two phase 3 randomized trials (PIONEER I, NCT01468207; PIONEER II, NCT01468233).
Evaluated weekly administration of adalimumab at 40 mg versus placebo over a 12-week period.
Weekly adalimumab (40 mg) achieved significantly higher clinical response rates than placebo at 12 weeks in both trials.
Serious adverse event rates occurred at balanced frequencies between the adalimumab and placebo groups.

Cite This Study

Kimball et al. (2016) studied this question.

synapsesocial.com/papers/69d7d4e8ba18484428d1814e https://doi.org/10.1056/nejmoa1504370

View Full Paper

Ask AI

Bookmark

Implication

Randomized trials demonstrate higher 12-week response rates with adalimumab in hidradenitis suppurativa, indicating therapeutic efficacy without added serious adverse events.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Discussion

Member takes

Implication

Key Points

Cite This Study

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider